Inactive Instrument

Highlights VIVUS, Inc.

Equities

VVUSQ

US9285513084

Pharmaceuticals

Highlights

Mar. 10	Vivus Bv, A Subsidiary of Vivus Llc Announces Qsiva Price Reduction Across Nordics and Poland	CI
Jan. 26	VIVUS LLC Announces the Results of a Randomized Trial Evaluating the Effect of QSYMIA	CI
Jan. 07	VIVUS Introduces Lower Pricing on QSYMIA at Costco Locations Across Hawaii	CI
25-09-04	VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome	CI
25-05-27	VIVUS Announces Qsymia Now Available at Costco Pharmacies Nationwide	CI
25-04-14	VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma	CI
25-03-10	VIVUS Launches QSYMIA in the United Arab Emirates	CI
24-10-23	VIVUS Announces Label Update for QSYMIA	CI
24-05-30	Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	CI
24-04-22	VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	CI
23-11-28	VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	CI
22-07-20	FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	CI
20-05-06	Vivus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-04-05	VitalTech Partners with VIVUS, Inc. to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules	CI
20-03-31	VIVUS, Inc. Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”	CI
20-03-03	Vivus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-03-02	VIVUS, Inc. Announces Completion of Patient Enrollment in a Phase 4 Clinical Study Designed to Evaluate the Safety and Efficacy of Qsymia	CI
20-02-19	VIVUS, Inc. and Alvogen Announce Commercial Launch of Qsymia®	CI
20-02-05	VIVUS, Inc. Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE with a 36-Month Shelf Life	CI
20-01-07	VIVUS, Inc. Announces New Study from the Toolbox Trial	CI
19-12-18	VIVUS, Inc. Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity	CI
19-11-20	VIVUS, Inc. Announces Results of a Clinical Study Demonstrating Patients with Binge-Eating Disorder or Bulimia Nervosa	CI
19-11-05	Vivus, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
19-10-07	VIVUS, Inc. Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe	CI
19-08-20	VIVUS, Inc. Announces Results of Pilot Clinical Study Demonstrating That Patients Receiving Qsymia Capsules	CI